The FDA’s approval for expanded use reinforces LP-310’s potential as a new therapeutic option for OLP and supports ongoing clinical development efforts.

Lipella Pharmaceuticals Inc. (LIPO), a clinical-stage biotechnology company, Wednesday said that the U.S. Food and Drug ...

Mayo Clinic researchers have identified a targeted therapy that could bring relief to people living with lichen planus, a ...

Boulder County Parks and Open Space officials announced Tuesday that the Lichen Loop at Heil Valley Ranch is closed due to ...

Lichen sclerosus was first coined by French dermatologist, Francois Hallopeau in 1889. Over time, it has been known by ...

Teaser: Off-label systemic agents may treat inflammatory autoimmune vulvar diseases such as lichen sclerosus and lichen ...

Lichen China Ltd. Class A ( ($LICN) ) has provided an announcement. Lichen China Limited announced a securities purchase agreement with ...

Built on the foundation of sustainability, the stunning new green color, titled Lichen, joins seven other colors of this ...

We recently compiled a list of the 12 AI News Investors Probably Missed. In this article, we are going to take a look at ...

中国厦门 - 作为一家知名的财务和税务服务提供商，Lichen China ...

中国厦门 - Lichen China Limited（纳斯达克代码：LICN），一家提供财务和税务服务的公司，目前市值537万美元，毛利率高达61%，宣布了一项注册直接发行A类普通股和预付权证的计划，预计筹集约340万美元。此次交易的股票定价为每股0.08美元，预计将于周三左右完成交割，具体取决于惯例条件。